

Memorial Sloan Kettering Cancer Center...

# **Integrative Cancer Care**

Gary Deng, MD, PhD Integrative Medicine Service

The 13th Annual Winter Lung Cancer Conference Feb 14, 2016, Miami, FL



## Disclosures

No relevant conflicts of interest to disclose.

72 year old man with stage 4 NSCLC on cisplatin and pemetrexed complains of chemo-induced nausea and peripheral neuropathy, back pain, anxiety, insomnia and fatigue.

Patient asks whether acupuncture, yoga, or meditation would be helpful.





### What would you tell the patient?

Acupuncture (Yes/No)
 Yoga (Yes/No)
 Meditation (Yes/No)









- Cancer patients are very interested in complementary therapies. When used properly, they improve patients' life and also help health care providers.
- A lot has happened in the last decade in terms of research. I will give a summary of the state of the science.
- The main question is no longer "does it work," but multi-dimensional: how it works, for whom it works, and how to apply it in clinical practice. I will use examples to show that, esp. how it relates to hospital operations.
- The bigger picture of the role integrative medicine plays in enhancing quality of cancer care. Call for actions.

## **Complementary Therapy Use**

Percent using complementary therapies, by age



National Health Interview Survey 2007

## PubMed Publications: 1980 to present



# Acupuncture

# > Pain > Nausea Vomiting

- > Dry mouth
- > Hot flashes
- > Anxiety
- > Insomnia
- > GI dysfunction
- > Lymphedema
- > Fatigue
- > Neuropathy

# **Mind-Body Therapy**

- > Meditation
- > Hypnosis
- > Guided Imagery
- > Breathing Exercises

> Qigong

For

- > Anxiety
- > Stress/Distress
- > Sleep
- > Depression
- > Pain
- > General Quality of Life

# **Massage Therapy**

- > Swedish massage
  - Reflexology
- > Lymphatic drainage
- › Myofascial release
- Shiatsu
- > Tuina
- > Reiki
- › Ayurvedic massage

# **Music Therapy**

### **Receptive or Participatory**

> Bring comfort and joy
> Ease fear
> Increase relaxation
> Enhance self-expression
> Lessen feelings of isolation and loneliness





# Yoga / Tai Chi

## **Acupuncture for Chronic Pa**

Figure. Results of the Individual Patient Data Meta-analysis

A Acupuncture vs sh			Participants	
Pain Type	Trials	Sham Acupuncture	Acupuncture	Standardized Me Difference (95% (
Headache	4	683	799	0.15 (0.07-0.24
Musculoskeletal	8	708	804	0.37 (0.27-0.46
Osteoarthritis	5	799	830	0.26 (0.17-0.34
Shoulder	3	312	295	0.62 (0.46-0.77
Overall (fixed-effects	estimate)			0.29 (0.24-0.33
Overall (random-effec	ts estimate)			0.34 (0.18-0.50



B Acupuncture vs no	acupuncture	Total No. of			
Pain Type	Trials	No Acupuncture	Acupuncture	Standardized Mea Difference (95% (	
Headache	5	2224	2408	0.42 (0.37-0.46	
Musculoskeletal	7	3739	4000	0.55 (0.51-0.58	
Osteoarthritis	6	1062	1164	0.57 (0.50-0.64	
Overall (fixed-effects	estimate)			0.51 (0.48-0.53	
Overall (random-effec	ts estimate)			0.51 (0.42-0.60	



JAN

### **Acupuncture for Chemo-Induced Peripheral Neuropathy**

Authors	Patients (n)	Design of the study	Intervention and control	Duration of intervention	Outcome(s)	Results
Alimi et al., 2003 [23]	90	Prospective randomized controlled trial	Auricular acupuncture versus placebo acupuncture and seeds	2 months	VAS pain score and medication consumption	True acupuncture better than placebo
Wong and Sagar, 2006 [24]	5	Prospective case series	Acupuncture (no control)	16 weeks (Two 6-week courses with a 4-week therapy free interval)	Pain score and WHO CIPN grade	Improvement
Xu et al., 2010 [25]	64	Controlled randomized trial	Acupuncture versus cobamamide	Not known	Questionnaire of peripheral neuropathy	Acupuncture better that cobamamide
Bao et al., 2011 [26]	1	Case report	Acupuncture (no control)	22 weeks	VAS pain score	No more symptoms
Donald et al., 2011 [27]	18	Retrospective case series	Acupuncture (no control)	6 weeks	Subjective symptoms	82% improved
Schroeder et al. 2012 [28]	, 11	Retrospective controlled nonrandomized trial	Acupuncture and best medical care versus best medical care	10 weeks	Nerve conduction studies	Acupuncture better than control
Tian et al., 2011 [29]	76	Controlled randomized trial	Warm acupuncture and moxibustion versus Neurotropin	Not known	Quality of life and neurotoxic symptoms	Acupuncture better than Neurotropin

TABLE 1: Characteristics of the studies involving the use of acupuncture in CIPN.

Legend: VAS: visual analog scale; FACT-G: Functional Assessment of Cancer Therapy-General.

### **Analgesic Effect of Acupuncture Is Mediated via Adenosine**



(Goldman et al, <u>Nat Neurosci.</u> 2010 Jul;13(7):883-8.)

### Inhibition of deaminase activity enhances acupuncture's effect



(Goldman et al, <u>Nat Neurosci.</u> 2010 Jul;13(7):883-8.)

## **Acupuncture and Functional MRI**







Wu et al. Radiology. 1999 Jul;212(1):133-41. Hy=hypothalamus, NA=amygdala, Nacs=nucleus accumbens



Map of brain response to 18 different acupuncture points.

PLoS One.</u> 2012;7(4):e32960. Characterizing acupuncture stimuli using brain imaging with FMRI--a systematic review and meta-analysis of the literature.

## **Acupuncture Reduces Chemo-Related Nausea & Vomiting**



## Insomnia

### Figure 3. Forest plot of comparison: I Acupuncture alone versus no treatment, outcome: I.I Frequency of improvement in sleep quality.

	Acupun	cture	No treat	ment		Odds Ratio	Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95%	CI
1.1.1 Acupressure								-
Chen 2009	95	100	35	100	50.9%	35.29 [13.13, 94.84]		
Tang 2007a Subtotal (95% Cl)	35	40 140	24	40 140	49.1% 100.0%	4.67 [1.51, 14.45] 13.08 [1.79, 95.59]		-
Total events	130		59					
Heterogeneity: Tau <sup>2</sup> =	= 1.77; Chi	z = 7.02	df = 1 (P =	= 0.008)	; I <sup>2</sup> = 86%	5		
Test for overall effect	Z = 2.53 (	P = 0.01	)					
Total (95% CI)		140		140	100.0%	13.08 [1.79, 95.59]		
Total events	130		59					
Heterogeneity: Tau <sup>2</sup> =	= 1.77; Chi	= 7.02	df = 1 (P :	= 0.008)	; I <sup>≥</sup> = 86%	5		10 11
Test for overall effect	Z= 2.53 (	P = 0.01	)				0.01 0.1 1 Favours control Favours	10 10 interven
Test for subgroup dif	ferences: N	Vot appl	licable				ravous comor ravous	mileiven

## Insomnia

#### Figure 4. Forest plot of comparison: 2 Acupuncture alone versus placebo or sham acupuncture, outcome: 2.1 Frequency of improvement in sleep quality.

	Acupune	cture	Placebo/sham acupund	ture		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
2.1.1 Acupressure							
Chen 1999	5	26	Ť	26	34.7%	5.95 [0.64, 55.03]	
Lin 2007 Subtotal (95% CI)	28	30 56	20	30 56	65.3% 100.0%	7.00 [1.38, 35.48] 6.62 [1.78, 24.55]	
Total events Heterogeneity: Tau² = Test for overall effect:			21 df = 1 (P = 0.91); I <sup>z</sup> = 0%				
restion overall ender.	2-2.02 (	- 0.00	.5)				
Total (95% CI)		56		56	100.0%	6.62 [1.78, 24.55]	-
Total events Heterogeneity: Tau² = Test for overall effect.	and the second se		21 df = 1 (P = 0.91); I <sup>z</sup> = 0%				0.01 0.1 1 10 100
Test for subgroup dif							Favours control Favours intervention

#### Acupuncture + other Other treatment alone Odds Ratio Odds Ratio Study or Subgroup Events Events Total Weight M-H, Random, 95% Cl M-H, Random, 95% CI Total 3.1.1 Needle acupuncture Cui 2003 58 52 60 60 6.6% 4.46 [0.91, 21.97] Du 2007 32 34 17 5.0% 20 2.82 [0.43, 18.57] Guo 2009 21 23 13 6.0% 7.27 [1.35, 39.05] 22 50 23 Jian 2005 46 30 8.6% 3.50 [0.93, 13.19] Liu 2001 47 56 17 12,1% 3.99 [1 45, 11.02] 30 Lu 1998 28 35 11 23 10.2% 4.36 [1.36, 13.98] 32 5.1% Luo 2006 30 29 32 1.55 [0.24, 9.97] 25 LY 2007 30 34 34 8.9% 2.70 [0.74, 9.83] 18 30 22 Ma 2006a 30 11.1% 0.55 [0:18, 1.62] Tian 2006 36 39 21 8.5% 10.29 [2.71, 39.10] - 39 30 22 6.2% Zhao 2010 28 30 5.09 [0.98, 26.43] Subtotal (95% CI) 423 350 88.5% 3.26 [1.93, 5.49] Total events 374 252 Heterogeneity: Tau\* = 0.27; Chi\* = 15.58, df = 10 (P = 0.11); I\* = 36% Test for overall effect: Z = 4.43 (P < 0.00001) 3.1.2 Electroacupuncture Lai 2010 30 30 2.1% 5.35 [0.25, 116.31] 28 30 Li 2005a 20 26 16 24 9.4% 1 67 [0.48, 5 79] 11.5% Subtotal (95% CI) 56 54 1.96 [0.62, 6.23] Total events 50 44 Heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 0.48, df = 1 (P = 0.49); l<sup>2</sup> = 0% Test for overall effect: Z = 1.15 (P = 0.25) Total (95% CI) 3.08 [1.93, 4.90] 479 404100.0% Total events 424 296 Heterogeneity: Tau<sup>2</sup> = 0.20; Chi<sup>2</sup> = 16.63, df = 12 (P = 0.16); l<sup>2</sup> = 28% 0.01 100 0.1 10 Test for overall effect: Z = 4.73 (P < 0.00001) Favours control Favours intervention Test for subgroup differences: Chi<sup>2</sup> = 0.61, df = 1 (P = 0.43), I<sup>2</sup> = 0%

#### Figure 5. Forest plot of comparison: 3 Acupuncture as adjunctive to other treatment versus other treatment alone, outcome: 3.1 Frequency of improvement in sleep quality.

<u>Cochrane Database Syst Rev.</u> 2012 Sep 12;9:CD005472. Acupuncture for insomnia.

### Mindfulness Meditation: Present-centered, nonjudgmental, awareness

Outcome	Meditation Program	Clinical Population	No. of Trials, Total (PO); PA (MA)	Direction (Magnitude) of Effect	Strength of Evidence	Favors Meditation	
Anxiety	Mindfulness	Various (n = 647)	8 (3); 7 (7)	↑(0% to +44%)	Moderate for improvement		
	Mantra	Various (n = 237)	3 (2); 3 (3)	Ø(-3% to +6%)	Low for no effect	<b> −−●−−</b>	
Depression	Mindfulness	Various (n = 806)	10 (4); 9 (8)	↑(-5% to +52%)	Moderate for improvement	⊢ ● – Ì	
	Mantra	Various (n = 440)	5 (1); 5 (3)	↑↓(-19% to +46%)	Insufficient	<b>⊢</b> ● − 1	
Stress/Distress	Mindfulness	Various (n = 735) <sup>a</sup>	9 (4); 8 (7)	↑(+1% to +21%)	Low for improvement		
	Mantra	Select (n=239)	4 (2); 4 (2)	Ø(-6% to +1%)	Low for no effect	<b>I</b>	
Negative Affect	Mindfulness	Various (n = 1140) <sup>b</sup>	14 (5); 12 (11)	↑(-1% to +44%)	Low for improvement	H•	
	Mantra	Various (n = 438) <sup>c</sup>	5 (2); 5 (0)	↑↓(-3% to +46%)	Insufficient		
Positive Affect	Mindfulness	Various (n = 293)	4 (0); 4 (4)	↑(+1% to +55%)	Insufficient	<b>I</b> • I	
	TM (mantra)	CHF (n=23)	1 (0); 1 (0)	Ø(+2%)	Insufficient		
Quality of Life	Mindfulness	Various (n = 346)	4 (2); 4 (3)	<b>↑(+5% to +28%)</b>	Low for improvement	<b>⊢</b> ●	
Attention	Mindfulness	Caregivers (n=21)	1 (0); 1 (0)	↑(+15% to +81%)	Insufficient		
Sleep	Mindfulness	Various (n = 578)	6 (2); 4 (4)	↑↓(-3% to +24%)	Insufficient	<b>⊢</b> ● −1	
Substance Use	TM	CAD (n = 201)	1 (0); 0 (0)	Ø	Insufficient		
Pain	Mindfulness	Select (n=341)	4 (2); 4 (4)	↑(+5% to +31%)	Moderate for improvement	<b>⊢</b> ● -	
	TM (mantra)	CHF (n=23)	1 (0); 1 (0)	Ø(-2%)	Low for no effect		
Weight	TM (mantra)	Select (n = 297)	3 (0); 2 (0)	Ø(-1% to +2%)	Low for no effect		

Meditation programs for psychological stress and well-being: a systematic review and meta-analysis.

-1

0 d Statistic (95% CI)

47 trials with 3515 participants, JAMA Intern Med. 2014 Mar;174(3):357-68.

## **Effects of Stress on Cancer**

#### Table 1

Representative studies on the effects of stress and stress-associated hormones on cancer.

Experimental condition	Species	Main biological effect	Cancer type	Effect on tumor growth	References
Immobilization stress	Mice	Increased angiogenesis	Ovarian	Increased growth	Thaker et al. (2006)
Enriched environment	Mice	Decreased proliferation	Skin, colon	Decreased tumor growth	Cao et al. (2010)
Restraint stress	Mice	Anchorage-independent survival	Ovarian	Increased growth and metastasis	Sood et al. (2010)
Force swim, surgical stress	Rat	Suppressed NK cell activity	Leukemia, breast	Increased growth	Ben-Eliyahu et al. (1999)
Restraint stress	Mice	Suppressed immune function	Skin	Increased susceptibility to UV-induced disease	Saul et al. (2005)
Restraint stress	Mice	Increased macrophage infiltration	Breast	Increased metastasis	Sloan et al. (2010)
Dopamine administration	Mice, Rat	Decreased angiogenesis	Gastric	Decreased growth	Chakroborty et al. (2004)
Depression	Human	Increased cortisol, IL-6	Ovarian	n/a	Lutgendorf et al. (2008a– c)
Psychological intervention	Human	Increased immune activity	Breast	Improved survival	Andersen et al. (2010)
Social support	Human	Increased immune activity	Ovarian	n/a	Lutgendorf et al. (2005)
Beta-blocker Administration	Human	n/a	Breast	Decreased mortality	Barron et al. (2011)
Stressful life events	Human	n/a	Breast	No association with cancer risk	Duijts et al. (2003)
Personality	Human	n/a	Breast	No association with cancer risk	Bleiker et al. (2008)
Stressful life events	Human	n/a	Breast	Association with cancer risk	Lillberg et al. (2003)
Stressful life events	Human	n/a	Breast	Association with cancer risk	Price et al. (2001)

## **Emerging Cancer Hallmarks and Enabling Characteristics**

• What happens elsewhere in the body can influence how cancer cells behave



# Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma



Nature Medicine - 12, 939 - 944 (2006)

# Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma



Red: endothelial cells Green: pericytes

### Control

### **Daily Stress**

### **Stress and Cancer: Animal Models**

 Src activation by β-adrenoreceptors is a key switch for tumor metastasis



### **Biobehavioral Pathways in Cancer**



Fig. 1. Heuristic framework for research on biobehavioral risk factor influences on clinical cancer course.

P. Green McDonald et al. / Brain, Behavior, and Immunity 30 (2013) S1–S9

**Neuro-imaging Studies of Meditation** 



### What would you tell the patient?

Acupuncture (Yes/No)
 Yoga (Yes/No)
 Meditation (Yes/No)

64 year old woman with stage 4 NSCLC, progression of disease after first line chemotherapy, now on nivolumab.

Patient wants to explore "all options" and asks whether she can take graviola, turmeric and probiotics.





### What would you tell the patient?

Graviola (Yes/No)
 Turmeric (Yes/No)
 Probiotics (Yes/No)





# **Graviola aka Soursop**

Leaves contain compounds that inhibit cancer cells in vitro Inhibit P-glycoprotein thus influence drug metabolism Neurotoxicity has been reported



# **Turmeric and Curcumin**

In vitro: effects on NK-kB, Stat3, mTOR, CDK, VEGF Poor bioavailability: needs special formulation Clinical data: activity in pancreatic cancer patients reported

OH

 $OCH_2$ 

Phase II trial of curcumin in patients with advanced pancreatic cancer

21 evaluable patients
1 stable dz for 18 m
1 marked yet brief
regression



Clin Cancer Res. 2008 Jul 15;14(14):4491-9.





# **Probiotics**

Saccharomyces boulardii reduces C. diff associated disease Bifidobacterium enhances effect of anti-PD-L1 antibody Bacteroidales enhances effect of anti-CTLA-4 antibody



# Bifidobacterium

Enhances effect of anti-PD-L1 antibody in melanoma mice model, possibly through altering dendritic cell activity, which in turn leads to improved tumor-specific CD8+ T-cell function.



### What would you tell the patient?

Graviola (Yes/No)
 Turmeric (Yes/No)
 Probiotics (Yes/No)



NIH	National Cer Complemen Integrative H	tary and lealth		Follo	w NCCIH	S ()
Home	Health Info	Research	Grants & Funding	Training	News	About NCCIH

#### **Clinical Practice Guidelines**

"Clinical practice guidelines are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances." (Institute of Medicine, 1990)

Stay Connected ► 🖄 💟 📑 Via email, RSS, Twitter<sup>®</sup>, or Facebook<sup>®</sup>

Search

#### Neurology

### Oncology

- Exercise Guidelines for Cancer Survivors & (Med Sci Sports Exerc)
- Integrative Oncology in Lung Cancer I (Chest)
- Integrative Oncology: Complementary Therapies and Botanicals & (Society for Integrative Oncology)
- Use of Integrative Therapies as Supportive Care in Breast Cancer Patients 
   (Journal of the National Cancer Institute) [391KB PDF]
  - Chiropractic Management of Fibromyalgia 🖗 (Council on Chiropractic Guidelines and Practice Parameters) [21KB PDF]
  - Chronic Pain Management @ (Anesthesiology) [699KB PDF]
  - Diagnosis and Treatment of Low-Back Pain 🖗 (Annals of Internal Medicine) [494KB PDF]

## Joint Commission's Pain Management Standard

Joint Commission

Requirement

### **Clarification to Standard PC.01.02.07**

Effective January 1, 2015, for Ambulatory Care, Critical Access Hospital, Home Care, Hospital, Nursing Care Centers, and Office-Based Surgery Practice Programs

Standard PC.01.02.07: The [organization] assesses and manages the [patient's] pain.

#### Revised Rationale for PC.01.02.07 (New for Ambulatory Care and Office-Based Surgery Practice)

The identification and management of pain is an important component of [patient]-centered care. [Patients] can expect that their health care providers will involve them in their assessment and management of pain. Both pharmacologic and nonpharmacologic strategies have a role in the management of pain. The following examples are not exhaustive, but strategies may include the following:

 Nonpharmacologic strategies: physical modalities (for example, acupuncture therapy, chiropractic therapy, osteopathic manipulative treatment, massage therapy, and physical therapy), relaxation therapy, and cognitive behavioral therapy

 Pharmacologic strategies: nonopioid, opioid, and adjuvant analgesics

**C EP 4** : The [organization] either treats the [patient's] pain or refers the [patient] for treatment.

## New Note for EP 4 (Additional Note for Nursing Care Centers)

**Note:** Treatment strategies for pain may include pharmacologic and nonpharmacologic approaches. Strategies should reflect a [patient]-centered approach and consider the patient's current presentation, the health care providers' clinical judgment, and the risks and benefits associated with the strategies, including potential risk of dependency, addiction, and abuse.



Clinicians

About Us

DONATE JOIN SIO MEMBERS

Search ....

OUR MISSION: TO ADVANCE EVIDENCE BASED, COMPREHENSIVE, INTEGRATIVE HEALTHCARE TO IMPROVE THE LIVES OF PEOPLE AFFECTED BY CANCER.

Researchers





#### **Clinical Practice Guidelines**

SIO is pleased to provide two new resources on integrative oncology. SIO developed new Clinical Practice Guidelines on the Use of Integrative Therapies as Supportive Care in Patients Treated for Breast Cancer,

published in November 2014. The guidelines are a resource for clinicians and patients to inform evidencebased decisions on the use of integrative therapies during breast cancer treatment. Researchers at US and Canadian evaluated the efficacy and safety of more than 80 therapies.

The Journal of the National Cancer Institute Monograph has released a special issue co-sponsored by SIO. The



Patients

#### Conference

Mark your calendar: SIO's 13th International Conference will be held November 5-7, 2016, with a theme of "Advancing the Global Impact of Integrative Onclolgy" in Miami, Florida. More information coming soon!

Thank you for making our 2015 conference such a success. More than 350 physicians, researchers, nurses, integrative medicine practitioners, patient advocates, and patients from 19 countries convened in Boston, Massachusetts, from November 14-17 at the 12th International Conference.

#### Events

Professional Development



13th International Conference of the Society for Integrative Oncology

Media Center

## **Integrative Medicine Enhances Cancer Care**

### **For Patients:**

- Helps reduce symptoms
- Promotes self-care
- Enhances quality of life
- Nurtures the well-being of body, mind, spirit
- Patients become 'ambassadors' of healthy lifestyle to family and friends

### For Cancer Care Professionals:

- Heals the healers and improves wellness so that they become more effective health care professionals
- Strengthens relationship with patients
- Enhances the overall quality of care to patients

